333 related articles for article (PubMed ID: 11727535)
1. T-cell-directed cancer vaccines: the melanoma model.
Wang E; Phan GQ; Marincola FM
Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
[TBL] [Abstract][Full Text] [Related]
2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
3. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
[TBL] [Abstract][Full Text] [Related]
5. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
6. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
7. Melanoma vaccines: the paradox of T cell activation without clinical response.
Nielsen MB; Marincola FM
Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigens and tumor vaccines: peptides as immunogens.
Slingluff CL
Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
13. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
14. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L
Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.
Maeurer MJ; Storkus WJ; Kirkwood JM; Lotze MT
Melanoma Res; 1996 Feb; 6(1):11-24. PubMed ID: 8640065
[TBL] [Abstract][Full Text] [Related]
16. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
18. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
20. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
